Family Capital Trust Co lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 100,736 shares of the healthcare product maker’s stock after selling 445 shares during the quarter. Abbott Laboratories comprises 2.5% of Family Capital Trust Co’s portfolio, making the stock its 11th largest holding. Family Capital Trust Co’s holdings in Abbott Laboratories were worth $4,897,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of ABT. Whittier Trust Co. lifted its holdings in shares of Abbott Laboratories by 1.7% in the first quarter. Whittier Trust Co. now owns 401,048 shares of the healthcare product maker’s stock worth $17,807,000 after buying an additional 6,751 shares in the last quarter. Century Capital Management LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $4,332,000. Comerica Securities Inc. bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $2,833,000. Tandem Investment Advisors Inc. boosted its position in shares of Abbott Laboratories by 3.2% in the first quarter. Tandem Investment Advisors Inc. now owns 225,566 shares of the healthcare product maker’s stock valued at $10,017,000 after acquiring an additional 7,009 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of Abbott Laboratories by 264.8% in the first quarter. AQR Capital Management LLC now owns 634,391 shares of the healthcare product maker’s stock valued at $28,173,000 after acquiring an additional 460,477 shares during the period. 71.50% of the stock is owned by institutional investors and hedge funds.

In other Abbott Laboratories news, insider Hubert L. Allen sold 4,600 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $50.79, for a total transaction of $233,634.00. Following the completion of the transaction, the insider now owns 105,479 shares of the company’s stock, valued at $5,357,278.41. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Sharon J. Bracken sold 2,000 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $49.16, for a total transaction of $98,320.00. Following the transaction, the insider now directly owns 28,806 shares of the company’s stock, valued at approximately $1,416,102.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 333,310 shares of company stock worth $16,857,255. Corporate insiders own 0.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Abbott Laboratories (ABT) Holdings Trimmed by Family Capital Trust Co” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/03/abbott-laboratories-abt-holdings-trimmed-by-family-capital-trust-co.html.

Shares of Abbott Laboratories (NYSE ABT) traded up 0.28% during mid-day trading on Tuesday, hitting $53.83. 2,583,694 shares of the stock were exchanged. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $54.80. The stock’s 50-day moving average price is $51.11 and its 200-day moving average price is $47.53. The company has a market cap of $93.53 billion, a P/E ratio of 75.39 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. The business had revenue of $6.64 billion for the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The business’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.55 earnings per share. Equities research analysts anticipate that Abbott Laboratories will post $2.49 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be given a dividend of $0.265 per share. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.97%. Abbott Laboratories’s payout ratio is 149.30%.

ABT has been the topic of several recent analyst reports. Citigroup Inc. initiated coverage on shares of Abbott Laboratories in a research note on Thursday, August 17th. They issued a “neutral” rating and a $53.00 target price on the stock. Jefferies Group LLC restated a “buy” rating and set a $55.00 price target on shares of Abbott Laboratories in a research report on Friday, June 16th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Friday, September 22nd. Barclays PLC boosted their price target on shares of Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, September 28th. Finally, BTIG Research began coverage on shares of Abbott Laboratories in a report on Wednesday, June 21st. They issued a “buy” rating and a $56.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Abbott Laboratories presently has an average rating of “Buy” and a consensus target price of $54.00.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.